IRVINE, Calif. & LIEGE, BELGIUM--(BUSINESS WIRE)--Regulatory News:
The discovery of effective biomarkers in cancer will have a significant impact on disease management. With the role of the blood-based prostate cancer biomarker PSA (prostate specific antigen) surrounded by controversy, new and more effective biomarkers of this leading cause of death in men are urgently needed. Epigenetic changes are closely linked to cancer and hold promise for prostate cancer diagnosis and management, the authors of a meta-analysis, published online in the leading urology journal, The Prostate (The Epigenetic promise for prostate cancer diagnosis. The Prostate. doi: 10.1002/pros.22459), have concluded.
The discovery of effective biomarkers in cancer will have a significant impact on disease management. With the role of the blood-based prostate cancer biomarker PSA (prostate specific antigen) surrounded by controversy, new and more effective biomarkers of this leading cause of death in men are urgently needed. Epigenetic changes are closely linked to cancer and hold promise for prostate cancer diagnosis and management, the authors of a meta-analysis, published online in the leading urology journal, The Prostate (The Epigenetic promise for prostate cancer diagnosis. The Prostate. doi: 10.1002/pros.22459), have concluded.
